The EIF2D Knockout SK-HEP-1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal cell population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line, engineered to disrupt the EIF2D gene. This loss-of-function model eliminates EIF2D protein expression, enabling precise dissection of its functions without altering the background of the host cells. The polyclonal nature preserves cellular heterogeneity, facilitating robust, population-level analyses that recapitulate tumor biology more closely than monoclonal isolates. This format is ideal for studies demanding uniform genetic modification across a diverse cell pool, strengthening the translational relevance of experimental findings.
SK-HEP-1 cells were established from ascitic fluid of a liver adenocarcinoma patient and are widely used as a tumorigenic hepatocellular carcinoma (HCC) model. These epithelial adenocarcinoma cells exhibit dysregulated proliferation and metastatic potential, mirroring key aspects of clinical HCC. Consequently, they serve as a valuable platform for investigating oncogenic signaling, metabolic reprogramming, and translational control mechanisms that underpin liver cancer progression. Their human origin and well-characterized genetic profile further support mechanistic studies and drug testing.
EIF2D functions in eIF2-independent translation initiation by binding the 40S ribosomal subunit and recruiting initiator tRNA, playing a critical role in IRES-mediated translation of mRNAs such as MYC, VEGF, and XIAP. Its activity is regulated by mTOR signaling, cellular stress, and growth factors, and it interacts with eIF3 and eIF1A within the pre-initiation complex. Through these interactions, EIF2D orchestrates selective synthesis of proteins required for cell cycle progression, proliferation, and stress adaptation. Notably, EIF2D-mediated translation is particularly important for the sustained expression of oncogenic factors under conditions that inhibit canonical initiation.
In hepatocellular carcinoma, EIF2D-mediated translational control contributes to tumor adaptation and progression. Knockout of EIF2D in SK-HEP-1 cells disrupts IRES-dependent production of oncogenic factors, enabling dissection of non-canonical translation in liver cancer pathology and validation of EIF2D as a therapeutic target. This model is particularly relevant given the frequent co-option of IRES-mediated translation in solid tumors during stress, and it provides a platform to test inhibitors targeting the EIF2D?C40S interface or related pathways.
This knockout model supports diverse applications, including studies of translational control in liver cancer, IRES-dependent gene regulation, drug target validation, and identification of translationally regulated oncogenes. Typical assays include western blotting for EIF2D and downstream targets, RT-qPCR of IRES-containing transcripts, polysome profiling to assess global translation changes, dual-luciferase IRES reporter assays, cell proliferation and migration assays, and RNA-seq to identify altered translational profiles. For additional details, please contact Ascent Research.
